InvestmentMay 6, 2026, 08:03 AM
Orchestra BioMed Secures $35M Strategic Capital for Pivotal Trials
AI Summary
Orchestra BioMed announced the receipt of a $15 million payment from Ligand Pharmaceuticals, completing a $35 million royalty financing commitment. This payment, combined with a separately announced $20 million investment from Medtronic, totals $35 million in fresh strategic capital received on May 1, 2026. The funding will support the continued execution of pivotal trials for the company's Atrioventricular Interval Modulation Therapy (AVIM Therapy) and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) programs.
Key Highlights
- Received $15M payment from Ligand, completing a $35M royalty financing commitment.
- Total capital received from Ligand to date is $40M, including a $5M equity purchase.
- Secured $35M in fresh strategic capital on May 1, 2026, including $20M from Medtronic.
- Funding supports continued execution of pivotal trials for AVIM Therapy and Virtue SAB.
- Ligand's CEO noted strong progress, including BACKBEAT Trial enrollment acceleration.
- AVIM Therapy and Virtue SAB target multi-billion-dollar annual global market opportunities.